Sensitivity, Specificity, and Predictors of Positive 68 Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis

Torre, 2015, Global cancer statistics, 2012, Cancer J Clin, 65, 87, 10.3322/caac.21262

Bartsch, 2001, Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria, Urology, 58, 417, 10.1016/S0090-4295(01)01264-X

Yu, 2014, Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature, Am J Nucl Med Mol Imaging, 4, 580

Beresford, 2010, A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence, Clin Oncol, 22, 46, 10.1016/j.clon.2009.10.015

Evangelista, 2013, Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis, Eur Urol, 63, 1040, 10.1016/j.eururo.2012.09.039

DeMarzo, 2003, Pathological and molecular aspects of prostate cancer, Lancet, 361, 955, 10.1016/S0140-6736(03)12779-1

Huang, 2003, Prostate adenocarcinoma presenting with inguinal lymphadenopathy, Urology, 61, 463, 10.1016/S0090-4295(02)02269-0

Wu, 2012, The clinical value of diffusion-weighted imaging in combination with T2-weighted imaging in diagnosing prostate carcinoma: a systematic review and meta-analysis, Am J Roentgenol, 199, 103, 10.2214/AJR.11.7634

Silver, 1997, Prostate-specific membrane antigen expression in normal and malignant human tissues, Clin Cancer Res, 3, 81

Bostwick, 1998, Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases, Cancer, 82, 2256, 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S

Evans, 2011, Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen, Proc Natl Acad Sci U S A, 108, 9578, 10.1073/pnas.1106383108

Plut, 2000, 111In-capromab pendetide: the evolution of prostate specific membrane antigen and the nuclear imaging of its 111In-labelled murine antibody in the evaluation of prostate cancer, Biodrugs, 13, 437, 10.2165/00063030-200013060-00007

Pandit-Taskar, 2014, 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer, Eur J Nucl Med Mol Imaging, 41, 2093, 10.1007/s00259-014-2830-7

Afshar-Oromieh, 2015, The diagnostic value of PET/CT imaging with the Ga-68-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging, 42, 197, 10.1007/s00259-014-2949-6

Eder, 2012, 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging, Bioconj Chem, 23, 688, 10.1021/bc200279b

Szabo, 2015, Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer, Mol Imaging Biol, 17, 565, 10.1007/s11307-015-0850-8

Rowe, 2016, Comparison of prostate-specific membrane antigen based F-18-DCFBC PET/CT to conventional imaging modalities for detection of hormone-naive and castration-resistant metastatic prostate cancer, J Nucl Med, 57, 46, 10.2967/jnumed.115.163782

Lu, 2013, Synthesis and SAR of 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates, Bioorg Med Chem Lett, 23, 1557, 10.1016/j.bmcl.2012.09.014

Afshar-Oromieh, 2014, Comparison of PET imaging with a Ga-68-labelled PSMA ligand and F-18-choline-based PET/CT for the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging, 41, 11, 10.1007/s00259-013-2525-5

Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, Br Med J, 339, b2700, 10.1136/bmj.b2700

Higgins, 2008

Whiting, 2011, QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies, Ann Intern Med, 155, 529, 10.7326/0003-4819-155-8-201110180-00009

Nyaga, 2014, Metaprop: a Stata command to perform meta-analysis of binomial data, Arch Public Health, 72, 39, 10.1186/2049-3258-72-39

Barendregt, 2013, Meta-analysis of prevalence, J Epidemiol Community Health, 67, 974, 10.1136/jech-2013-203104

Higgins, 2003, Measuring inconsistency in meta-analyses, Br Med J, 327, 557, 10.1136/bmj.327.7414.557

Miller, 1978, The inverse of the Freeman-Tukey double arcsine transformation, Am Stat, 32, 138

Dwamena B. Midas: a program for meta-analytical integration of diagnostic accuracy studies in Stata. Ann Arbor, MI: Division of Nuclear Medicine, Department of Radiology, University of Michigan Medical School; 2007.

Bluemel, 2016, 68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET/CT, Clin Nucl Med, 41, 515, 10.1097/RLU.0000000000001197

Budaus, 2016, Initial experience of 68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy, Eur Urol, 69, 393, 10.1016/j.eururo.2015.06.010

Ceci, 2015, Ga-68-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?, Eur J Nucl Med Mol Imaging, 42, 1284, 10.1007/s00259-015-3078-6

Demirkol, 2015, Prostate-specific membrane antigen-based imaging in prostate cancer: impact on clinical decision making process, Prostate, 75, 748, 10.1002/pros.22956

Dietlein, 2015, Comparison of [18F]DCFPyL and [68Ga]-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer, Mol Imaging Biol, 17, 575, 10.1007/s11307-015-0866-0

Eiber, 2015, Evaluation of hybrid Ga-68-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy, J Nucl Med, 56, 668, 10.2967/jnumed.115.154153

Freitag, 2016, Comparison of hybrid Ga-68-PSMA PET/MRI and Ga-68-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer, Eur J Nucl Med Mol Imaging, 43, 70, 10.1007/s00259-015-3206-3

Giesel, 2015, PSMA PET/CT with Glu-urea-Lys-(Ahx)-[Ga-68(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer, Eur J Nucl Med Mol Imaging, 42, 1794, 10.1007/s00259-015-3106-6

Herlemann, 2016, 68Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer, Eur Urol, 70, 553, 10.1016/j.eururo.2015.12.051

Kabasakal, 2015, Evaluation of PSMA PET/CT imaging using a Ga-68-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging, Nucl Med Commun, 36, 582, 10.1097/MNM.0000000000000290

Maurer, 2016, Diagnostic efficacy of 68gallium-PSMA positron emission tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer, J Urol, 195, 1436, 10.1016/j.juro.2015.12.025

Morigi, 2015, Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy, J Nucl Med, 56, 1185, 10.2967/jnumed.115.160382

Pfister, 2016, Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with 68Ga-PSMA-HBED-CC than with 18F-fluoroethylcholine PET/CT, Eur J Nucl Med Mol Imaging, 43, 1410, 10.1007/s00259-016-3366-9

Sachpekidis, 2016, 68Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer, Eur J Nucl Med Mol Imaging, 43, 1288, 10.1007/s00259-015-3302-4

Sahlmann, 2016, Biphasic 68Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma, Eur J Nucl Med Mol Imaging, 43, 898, 10.1007/s00259-015-3251-y

Sterzing, 2016, Ga-68-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients, Eur J Nucl Med Mol Imaging, 43, 34, 10.1007/s00259-015-3188-1

van Leeuwen, 2016, 68Ga-Prostate-specific membrane antigen has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment, BJU Int, 117, 732, 10.1111/bju.13397

Verburg, 2016, Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score, Eur J Nucl Med Mol Imaging, 43, 397, 10.1007/s00259-015-3240-1

D’Amico, 1998, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, 280, 969, 10.1001/jama.280.11.969

Hovels, 2008, The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis, Clin Radiol, 63, 387, 10.1016/j.crad.2007.05.022

Brogsitter, 2013, 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients, Eur J Nucl Med Mol Imaging., 40, S18, 10.1007/s00259-013-2358-2

Jadvar, 2013, Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations, Eur J Nucl Med Mol Imaging, 40, S5, 10.1007/s00259-013-2361-7

Mohsen, 2013, Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature, BJU Int, 112, 1062, 10.1111/bju.12279

Pinaquy, 2015, Comparative effectiveness of [18F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer, Prostate, 75, 323, 10.1002/pros.22921

Schumacher, 2015, [11C]Acetate positron emission tomography-computed tomography imaging of prostate cancer lymph-node metastases correlated with histopathological findings after extended lymphadenectomy, Scand J Urol, 49, 35, 10.3109/21681805.2014.932840

European Association of Urology. Guidelines on prostate cancer; 2015. http://uroweb.org/guideline/prostate-cancer/.

Afshar-Oromieh, 2013, PET/MRI with a Ga-68-PSMA ligand for the detection of prostate cancer, Eur J Nucl Med Mol Imaging, 40, 1629, 10.1007/s00259-013-2489-5

Beheshti, 2013, Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics, J Nucl Med, 54, 833, 10.2967/jnumed.112.110148

Krause, 2008, The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer, Eur J Nucl Med Mol Imaging, 35, 18, 10.1007/s00259-007-0581-4

Heidenreich, 2014, EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer, Eur Urol, 65, 467, 10.1016/j.eururo.2013.11.002

Cromphout, 2016, Probability of positive PET imaging with a [68Ga]-labelled PSMA ligand based on PSA value in patients with biochemical recurrent prostate cancer after radical prostatectomy, Eur Urol Suppl, 15, e565, 10.1016/S1569-9056(16)60567-5

Paffen, 2016, Evaluation of detection rate of 68Ga-PSMA PET/CT for biochemical recurrence after radical prostatectomy, Eur Urol Suppl, 15, e561, 10.1016/S1569-9056(16)60563-8

Eiber, 2016, Simultaneous Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer, Eur Urol, 70, 829, 10.1016/j.eururo.2015.12.053